Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loading-dose versus standard-dose lithium carbonate plus quetiapine in acute mania
IRCT20181204041847N2Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- May 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of lithium carbonate and quetiapine in bipolar I disorder (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Clinical response in acute mania. Started May 2023; status: completed.
02
Drugs
lithium carbonatequetiapine
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on IRCT20181204041847N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181204041847N2.